New drug trial aims to halt rare, debilitating nerve disease
NCT ID NCT07223203
Summary
This study is testing an investigational drug called nucresiran for people with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), a rare disease that causes progressive nerve damage. The goal is to see if nucresiran can slow or stop the worsening of nerve function, improve quality of life, and better control the underlying disease compared to another available treatment. About 125 participants will be enrolled globally to evaluate the drug's effectiveness and safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Trial Site
RECRUITINGBoston, Massachusetts, 02118u, United States
Conditions
Explore the condition pages connected to this study.